List of Excipients in Branded Drug METHYLDOPA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chartwell RX LLC	METHYLDOPA	methyldopa	62135-321	ANHYDROUS CITRIC ACID
Chartwell RX LLC	METHYLDOPA	methyldopa	62135-321	CELLULOSE, MICROCRYSTALLINE
Chartwell RX LLC	METHYLDOPA	methyldopa	62135-321	ETHYLCELLULOSE
Chartwell RX LLC	METHYLDOPA	methyldopa	62135-321	HYPROMELLOSE

Generic Drugs Containing METHYLDOPA

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	methyldopa	0378-0611	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	methyldopa	0378-0611	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	methyldopa	0378-0611	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	methyldopa	0378-0611	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in METHYLDOPA?

# Of NDCs	Excipient
3	CALCIUM SULFATE
3	CELLULOSE, MICROCRYSTALLINE
1	CITRIC ACID
2	CITRIC ACID MONOHYDRATE

Methyldopa Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Methyldopa is an established generic antihypertensive with limited patent barriers, low active-pharmaceutical-ingredient cost, and modest clinical differentiation. The strongest commercial opportunities are in formulation quality, pediatric and geriatric usability, low-dose tablets, oral liquids, stability control, and supply reliability rather than exclusivity-based pricing.

What is the FDA regulatory status of methyldopa?

Methyldopa is an FDA-approved prescription antihypertensive marketed primarily as immediate-release oral tablets in 125 mg, 250 mg, and 500 mg strengths. The drug is also available through generic abbreviated new drug applications (ANDAs). FDA labeling identifies methyldopa as an antihypertensive used alone or with other agents and recognizes its historical use in hypertension during pregnancy.[1]

Attribute	Methyldopa status
Active ingredient	Methyldopa
Primary therapeutic class	Centrally acting alpha-2 adrenergic agonist prodrug
Common dosage form	Immediate-release oral tablet
Common strengths	125 mg, 250 mg, 500 mg
FDA pathway	Original NDA and multiple generic ANDAs
Brand reference	Aldomet
NCE exclusivity	Expired
Current commercial model	Generic prescription market
Major patent barrier	None apparent for the core molecule or conventional tablet
Key formulation issue	Oxidative degradation and product discoloration

Methyldopa is converted centrally to alpha-methylnorepinephrine, which reduces sympathetic outflow. Its use has declined relative to newer antihypertensives because of sedation, orthostatic effects, hepatotoxicity concerns, hemolytic anemia risk, and a less convenient dosing profile. It remains clinically relevant in selected pregnancy and specialty settings.[1,2]

What patents protect methyldopa products?

The core methyldopa molecule, conventional oral tablets, and historical Aldomet patent estate are no longer meaningful sources of market exclusivity. Commercial protection now depends primarily on manufacturing quality, formulation know-how, trademarks, supply contracts, and regulatory execution.

When does methyldopa lose exclusivity?

Methyldopa lost its original small-molecule exclusivity decades ago. The active ingredient is a mature generic compound, and standard tablet products have long been subject to ANDA competition.

The key commercial implications are:

• No remaining NCE exclusivity protects the molecule.
• Any historical composition-of-matter protection has expired.
• Conventional immediate-release tablets are vulnerable to multiple generic suppliers.
• New patent protection would need to cover a genuinely novel formulation, delivery system, manufacturing process, or specific clinical use.
• A new patent would not prevent ordinary generic competition unless the generic product practiced the claimed invention.

FDA Orange Book listings should be reviewed by product and strength before launch because listed patents can vary by NDA, formulation, and method of use.[3] For a conventional methyldopa tablet, however, the practical patent risk is substantially lower than for recently approved branded medicines.

How many patents cover methyldopa?

The number of historically issued methyldopa patents is not a useful proxy for current market protection. The commercially relevant question is whether an unexpired patent is listed against an FDA-approved reference product or would be infringed by a proposed product.

Patent category	Current commercial relevance
Methyldopa composition of matter	Low; historical protection expired
Conventional immediate-release tablet	Low
Standard tablet excipient combinations	Low unless narrowly claimed and unexpired
Modified-release formulation	Potentially relevant if newly patented
Oral liquid formulation	Potentially relevant if a novel, non-obvious system is developed
Manufacturing and impurity control	Potentially relevant as trade secret or process patent
Method-of-use claims	Limited value unless tied to a specific, enforceable indication
Device or packaging claims	Possible, but generally weak as a basis for broad market exclusivity

A sponsor pursuing a new methyldopa product should conduct a current patent search across FDA Orange Book records, USPTO Patent Center, WIPO Patentscope, and major national patent offices. Patent status cannot be inferred from the age of the drug alone.

What excipients are important in methyldopa tablets?

The principal excipient strategy should address oxidation, dose uniformity, mechanical robustness, swallowability, and protection from moisture and light.

Methyldopa contains phenolic functionality and is susceptible to oxidation. Oxidative degradation can produce discoloration and impurity growth. The risk increases with oxygen exposure, elevated temperature, light, alkaline microenvironments, trace metals, and certain processing conditions.

Recommended excipient design objectives

Formulation objective	Excipient or process approach	Commercial rationale
Control oxidation	Low-peroxide excipients, oxygen-controlled processing, protective packaging	Reduces color change and impurity formation
Improve tablet strength	Microcrystalline cellulose, suitable binders, optimized compression	Supports transport and generic quality
Manage disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Preserves immediate-release performance
Improve flow	Colloidal silicon dioxide, controlled granulation	Supports content uniformity
Reduce sticking	Magnesium stearate at controlled concentration and mixing time	Improves manufacturing yield
Protect from light	Opaque film coat, blister, or bottle system	Reduces photodegradation risk
Control moisture	High-barrier blister or tightly closed bottle with desiccant where justified	Improves shelf life
Improve swallowability	Film coating, smaller tablet geometry, score line	Supports geriatric adherence
Improve identification	Color and imprinting system compatible with stability	Reduces medication-error risk

Excipient selection should use pharmaceutical-grade materials with controlled peroxide values and metal content. Oxidative impurities in excipients can create avoidable variability. The final formulation should be tested under accelerated and long-term conditions for assay, degradation products, dissolution, hardness, friability, disintegration, and appearance.

A direct-compression platform may reduce manufacturing complexity, but wet granulation can improve content uniformity and tablet robustness when low-dose strengths are produced. The 125 mg strength presents the greatest risk of blend uniformity problems because the active represents a smaller fraction of the total tablet mass.

What formulations are protected by methyldopa excipient strategy?

The most attractive formulation opportunities are not standard 250 mg and 500 mg tablets. They are products that solve specific handling, adherence, or patient-population problems.

Pediatric and geriatric oral liquids

A ready-to-use oral solution or suspension could address patients who cannot swallow tablets. The principal technical problem is chemical stability in water. Methyldopa oxidation, pH sensitivity, microbial control, taste, and packaging compatibility would need to be managed together.

A commercial oral liquid could use:

• A buffered pH range selected through forced-degradation studies.
• A suitable antioxidant system, subject to safety and labeling review.
• Chelation control where trace metals contribute to oxidation.
• A preservative system compatible with the target population.
• Flavor and sweetener systems that do not accelerate degradation.
• Amber bottles, unit-dose cups, or oral syringes.
• A short in-use period if long-term stability is not demonstrated.

An extemporaneous suspension is easier to commercialize than a fully optimized solution but creates dose-uniformity and resuspendability requirements. A sponsor would need to demonstrate that the product remains homogeneous after storage and ordinary patient handling.

Low-dose and split-tablet products

A 125 mg tablet with a functional score line could improve titration and reduce waste. Opportunities include:

• Better weight and size control.
• Verified splitability under USP testing.
• A film coat that does not compromise breaking force.
• Packaging that prevents confusion between 125 mg and 250 mg strengths.
• Tablet markings designed for older patients and caregivers.

This is a limited exclusivity opportunity but may support formulary adoption and pharmacy substitution.

Modified-release methyldopa

A once-daily or twice-daily modified-release product could improve adherence, but the commercial case is difficult. Methyldopa is an older drug with a shrinking market, and modified release would require pharmacokinetic, food-effect, dose-proportionality, and clinical bridging work.

Potential technologies include hydrophilic matrix tablets, multiparticulates, coated pellets, and osmotic systems. The formulation must avoid dose dumping and preserve predictable exposure in patients with variable gastrointestinal transit. A modified-release product could qualify for formulation patents if the release system is novel and non-obvious, but it would face reimbursement and prescriber-adoption challenges.

What manufacturing and IP barriers affect methyldopa?

Methyldopa does not have a major active-molecule barrier, but manufacturing quality can still create meaningful competitive separation.

API and impurity control

Important controls include:

• Optical purity and stereochemical consistency.
• Residual solvents.
• Related substances and oxidative degradants.
• Trace metals.
• Particle-size distribution.
• Bulk density and flow properties.
• Storage under controlled temperature and humidity.
• Protection from oxygen and light during handling.

The API is relatively inexpensive, so the economic advantage comes from yield, low rejection rates, stable supply, and reliable release testing. A manufacturer with validated impurity control can reduce regulatory observations and supply interruptions.

Process patents versus trade secrets

A new manufacturing process could be patentable if it materially improves yield, purity, stereochemical control, or waste reduction. In practice, much of the value may be better protected as confidential process know-how because the generic tablet market has limited pricing power.

Potentially protectable areas include:

• Low-oxidation API isolation.
• Reduced-metal-contact processing.
• Controlled crystallization.
• Particle engineering for direct compression.
• Low-peroxide excipient qualification.
• Oxygen-reduced blending and packaging.
• Stability-indicating analytical methods.

Process claims must be assessed against prior art and the ability of competitors to design around them.

What is the Orange Book status of methyldopa?

The Orange Book is relevant for identifying reference-listed drugs, approved strengths, dosage forms, therapeutic equivalence ratings, and any listed patents or exclusivity.[3] Methyldopa’s commercial profile is that of a mature generic product, not a protected branded product.

A launch review should verify:

1. The relevant reference-listed drug for each strength.
2. Whether any patent is listed against the selected reference product.
3. Whether the proposed formulation is therapeutically equivalent to the reference product.
4. Whether the product requires a 505(b)(2) application rather than an ANDA.
5. Whether the labeling includes pregnancy, hepatic, hematologic, and sedation-related warnings.
6. Whether the desired oral liquid or modified-release dosage form has a suitable reference product.

A conventional tablet that matches the reference product in dosage form, route, strength, performance, and labeling is more likely to fit the ANDA pathway. A new liquid, extended-release product, or materially different clinical use may require a different regulatory strategy.

Which companies are challenging methyldopa patents?

No material current patent challenge is expected to drive the methyldopa market because the core product is already generic and historical exclusivity has expired. Generic competition is more likely to arise through routine ANDA filings than through high-value Paragraph IV litigation.

What is the Paragraph IV risk for methyldopa?

Paragraph IV litigation risk is low for standard methyldopa tablets unless a sponsor lists a new formulation or method-of-use patent. A Paragraph IV certification would be commercially relevant only if:

• An unexpired patent is listed against the reference product.
• The proposed product infringes the listed claim.
• The patent owner brings suit within the statutory period.
• The formulation has sufficient market value to justify litigation.

For a new liquid or modified-release product, patent risk could increase because the sponsor may seek formulation claims. The commercial value of those claims would depend on whether the product gains reimbursement, clinical adoption, or a differentiated indication.

What patent litigation and settlement agreements affect methyldopa?

Methyldopa has no widely recognized current patent-litigation pattern comparable to newer branded drugs. There is no evident settlement-driven generic entry schedule that controls the conventional methyldopa tablet market.

Any diligence should distinguish between:

• Expired historical Aldomet litigation.
• Patent cases involving unrelated alpha-2 agonists.
• Litigation over a newly developed methyldopa formulation.
• Product-liability or manufacturing cases, which do not create market exclusivity.
• ANDA litigation involving another drug with a similar name.

Settlement agreements would matter only if tied to a live listed patent and a commercially meaningful product. For ordinary methyldopa tablets, that condition is unlikely.

How does methyldopa compare with competing antihypertensives?

Methyldopa competes clinically with labetalol, nifedipine, hydralazine, and other antihypertensives used in pregnancy or specialized settings. It competes commercially with inexpensive generic products across several classes.

Drug	Typical commercial position	Methyldopa comparison
Methyldopa	Low-cost, established generic	Familiar but limited by sedation and dosing burden
Labetalol	Widely used in pregnancy and general hypertension	Often more commercially attractive to prescribers
Nifedipine extended release	Common pregnancy and chronic hypertension option	Stronger adherence profile
Hydralazine	Acute or selected chronic use	Different tolerability and dosing profile
ACE inhibitors/ARBs	Broad chronic hypertension use	Not interchangeable in pregnancy
Thiazide diuretics	Low-cost first-line treatment	Different mechanism and patient positioning

Methyldopa’s best commercial niche is not broad first-line hypertension. It is a reliable, low-cost product for selected patients where clinicians value its historical pregnancy experience or need an alternative agent.

What revenue exposure and commercial opportunities exist?

Methyldopa revenue is unlikely to support a large premium-priced product without meaningful clinical or delivery differentiation. The opportunity is more suitable for generic manufacturers, contract manufacturers, specialty pharmacies, and companies with hospital or government procurement access.

Attractive opportunities

• Dual-source or regional supply contracts.
• Improved 125 mg and 250 mg tablet platforms.
• Pediatric oral liquid.
• Geriatric-friendly packaging and tablet design.
• Unit-dose hospital packaging.
• Stable product for tropical or high-humidity markets.
• Low-cost combination packs with complementary antihypertensives.
• Contract manufacturing using validated low-oxidation processes.
• Export products for markets where methyldopa remains commonly prescribed.
• Reformulation under a 505(b)(2) pathway where a clinically justified dosage-form change exists.

Less attractive opportunities

• Premium pricing for an ordinary immediate-release tablet.
• Large clinical programs without a differentiated indication.
• Broad patent strategies based only on routine excipient substitutions.
• Modified release without a clear adherence or pharmacoeconomic advantage.
• Oral liquids that rely on unstable aqueous chemistry.
• Products dependent on a single API source.

Revenue exposure is primarily volume-driven. Margin depends on manufacturing yield, API procurement, regulatory compliance, channel access, and the number of competing generic suppliers.

How strong is the methyldopa patent estate?

The core methyldopa patent estate is weak from a current market-exclusivity perspective. A new formulation estate could be moderate if it covers a clinically valuable dosage form and includes robust composition, process, and use claims.

Estate component	Relative strength
Core molecule	Very low
Standard tablets	Very low
Novel oral liquid	Moderate, if stability and composition claims are defensible
Modified release	Moderate, subject to prior art and clinical adoption
Manufacturing process	Moderate as trade secret; variable as patent
Packaging	Low to moderate
Method of use	Usually low unless indication and claim scope are narrow but valuable
Trademark and supply position	Commercially useful but not patent exclusivity

Key Takeaways

• Methyldopa is a mature generic antihypertensive with no meaningful core-molecule exclusivity.
• Standard 125 mg, 250 mg, and 500 mg immediate-release tablets are primarily price and supply businesses.
• Excipient strategy should focus on oxidation control, low-peroxide inputs, light protection, moisture control, and dose uniformity.
• Pediatric oral liquids and geriatric-friendly tablets offer the clearest formulation opportunities.
• Modified-release development could create patentable subject matter but carries substantial clinical and commercial risk.
• Paragraph IV litigation and settlement risk are low for conventional tablets.
• The strongest defensible assets are formulation know-how, process control, impurity management, packaging, and reliable distribution.
• Methyldopa is better suited to disciplined generic manufacturing and targeted reformulation than to a broad premium-drug strategy.

FAQs About Methyldopa Formulation and Commercialization

Can methyldopa be formulated as an oral suspension?

Yes. An oral suspension is technically feasible, but the sponsor must control oxidation, sedimentation, redispersibility, microbial quality, taste, dose uniformity, and in-use stability.

Is methyldopa suitable for pediatric drug development?

It may be suitable for selected pediatric hypertension settings, particularly where an oral liquid is needed. Commercial value depends on clinical demand, dosing guidance, and the ability to obtain a regulatory advantage.

Which excipient is best for preventing methyldopa oxidation?

No single excipient can be selected without formulation testing. A controlled pH, low-peroxide excipient system, trace-metal control, oxygen limitation, and protective packaging should be evaluated as an integrated package.

Can a methyldopa oral liquid receive new patent protection?

Potentially. Patentability would depend on a novel and non-obvious composition, stability profile, delivery system, or manufacturing process. Routine syrup or suspension ingredients would generally provide weak protection.

Is methyldopa still used for hypertension during pregnancy?

Yes. Methyldopa remains a recognized option in pregnancy-related hypertension, although treatment selection depends on current clinical guidance, patient-specific factors, tolerability, and competing agents.[2]

References

1. U.S. National Library of Medicine. (2024). Methyldopa tablet prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
2. American College of Obstetricians and Gynecologists. (2020). ACOG practice bulletin no. 203: Chronic hypertension in pregnancy. Obstetrics & Gynecology, 133(1), e26-e50.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.